FDA Recommends Recall of Artificial Eye Ointment for Potential Bacterial Contamination

Article

This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.

FDA is warning consumers and health care professionals of the use of Delsam Pharma’s Artificial Eye Ointment because of potential bacterial contamination. This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.

These over-the-counter products are manufactured by Global Pharma Healthcare Private Limited and are intended to be sterile. The use of the ointment can increase the risk of eye infections that can result in blindness according to FDA, and patients who have signs or symptoms of an eye infection should talk to their health care provider or seek medical care immediately warns the agency. FDA recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment on February 22, 2023.

Source: FDA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
© 2025 MJH Life Sciences

All rights reserved.